MRNA Moderna, Inc.
Moderna, Inc. (MRNA) is expected to report earnings on October 30, 2026, before the market open. The consensus earnings estimate is a loss of $1.38 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +9.5% since its last earnings release on July 31, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Moderna, Inc.
Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale.
Sector
Healthcare
Industry
Biotechnology